MaraBio Systems
Salt Lake City, US · Delaware corporation · 1 known investors
Find your way into MaraBio Systems
MARAbio develops a blood test for mothers that detects Maternal Autoantibody Related Autism (MARA) by identifying a cluster of antibodies, aiming to predict the likelihood of MARA in a child before clinical symptoms appear. The company is also researching therapeutic interventions for MARA.
Founders & leadership
MP
Michael PaulinExecutive
Board
MK
Michael KaufmanBoard director
VF
Vincent ForlenzaBoard director
CN
Craig NemiroffBoard director
GP
Gail PageBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$19.1M disclosed across 1 round · 2024
▶$19.1MraisedOct 2024 · 25 investors · BiotechnologyRule 506(b)
▶$19.1MraisedOct 2024 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vincent ForlenzaDirector
- Michael PaulExecutive Officer, Director
- Michael KaufmanDirector
- Craig NemiroffDirector
- Gail PageDirector
- Offering amount
- $29M
- Amount sold
- $19.1M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does MaraBio Systems do?
- MARAbio develops a blood test for mothers that detects Maternal Autoantibody Related Autism (MARA) by identifying a cluster of antibodies, aiming to predict the likelihood of MARA in a child before clinical symptoms appear. The company is also researching therapeutic interventions for MARA.
- Who are MaraBio Systems's investors?
- MaraBio Systems's investors include Moai Capital.
- How much funding has MaraBio Systems raised?
- MaraBio Systems has disclosed $19.1M raised across 1 round.
- Where is MaraBio Systems headquartered?
- MaraBio Systems is headquartered in Salt Lake City, US.